肺动脉瓣置换:单中心外科瓣膜与经导管瓣膜的比较
单中心回顾性分析2010年1月至2015年12月224例肺动脉瓣置换患者(外科组100例,经导管组124例),比较生存、再手术、再干预、住院费用及血流动力学。两组无死亡,再干预率相似;外科组住院更长,经导管组感染性心内膜炎发生率和费用更高。
要点
- 两组无死亡,4年累积免于再干预率相似(p=0.98)。
- 经导管组感染性心内膜炎发生率4.8%,外科组0%(p<0.001)。
- 经导管组住院费用更高(57221±13091美元 vs 44366±16519美元,p<0.001)。
核心结论
- 外科与经导管肺动脉瓣置换的血流动力学表现相似,再干预率相似;外科组住院时间更长,经导管组感染性心内膜炎发生率、住院费用和植入失败率更高。
研究设计与样本
- 单中心回顾性研究,2010年1月至2015年12月共224例肺动脉瓣置换患者,外科组100例,经导管组124例。
主要发现
- 两组均无死亡。
- 外科组患者更年轻(12±7岁 vs 19±13岁,p<0.001)且体表面积更小(1.2±0.5 m² vs 1.4±0.5 m²,p<0.001),但植入瓣膜中位尺寸相似(23 mm[四分位距21至27 mm] vs 22 mm[四分位距20至22 mm])。
- 4年累积免于再干预率两组相似(p=0.98)。
- 34例因冠状动脉压迫或流出道直径过大未能植入经导管瓣膜。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transcatheter pulmonary valve replacement (TPVR) is increasingly utilized to address residual or recurrent right ventricular outflow tract pathology in congenital heart disease patients. We aimed to evaluate clinical outcomes and resource utilization comparing TPVR to surgical pulmonary valve replacement (SPVR) for this patient population. METHODS: From January 2010 until December 2015, 224 patients underwent pulmonary valve replacement (SPVR = 100 and TPVR = 124). These groups were assessed and compared for survival, reoperation, reintervention (surgical or catheter based), hospital costs, and hemodynamic performance. RESULTS: There were no mortalities in either group. Despite SPVR patients being significantly younger (12 ± 7 years of age versus 19 ± 13 years of age; p < 0.001) and smaller (body surface area 1.2 ± 0.5 m2 versus 1.4 ± 0.5 m2; p < 0.001), they had similar median valve size implanted (23 mm [interquartile range, 21 to 27 mm) versus 22 mm [interquartile range, 20 to 22 mm]). There was no difference in the adjusted peak gradient (SPVR 24.1 ± 15.1 mm Hg versus TPVR 20.7 ± 11.4 mm Hg; p = 017) at last follow-up. Cumulative freedom from reintervention at 4 years was similar between groups (p = 0.98). TPVR could not be placed in 34 patients either due to coronary compression or excessive outflow tract diameter. SPVR patients had longer hospital length of stay (4.1 ± 1.8 days versus 1.2 ± 0.7 days; p < 0.001). TPVR patients had higher rates of infective endocarditis (4.8% versus 0%; p < 0.001) and overall hospital costs ($57,221 ± $13091 versus $44,366 ± $16,519; p < 0.001). CONCLUSIONS: Hemodynamic performance is similar between SPVR and TPVR with similar rates of reintervention. While SPVR patients have a longer hospital length of stay, TPVR was associated with higher rates of infective endocarditis, hospital costs, and failure to implant.
引用
- Sharma V, Griffiths ER, Eckhauser AW, et al. Pulmonary Valve Replacement: A Single-Institution Comparison of Surgical and Transcatheter Valves. Ann Thorac Surg. 2018. PMID: 29733826. doi:10.1016/j.athoracsur.2018.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。